# Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

> **NCT02892019** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 79 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Indacaterol acetate 75 μg
- **DRUG:** Indacaterol acetate 150 μg

## Key facts

- **NCT ID:** NCT02892019
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2019-06-19
- **Final completion:** 2019-07-17
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02892019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02892019, "Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02892019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*